Gene Therapy Trial for Cancer
Phase 2
285
about 9.6 years
18–72
1 site in MD
What this study is about
This trial is testing a new treatment that involves genetically engineering your own T-cells to fight cancer. It's being done in people whose cancer hasn't responded to standard treatments. The goal is to see if gene therapy can shrink tumors.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Individual Patient TCR-Transduced PBL
- 2.Take Aldesleukin
- 3.Take Cyclophosphamide
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
aldesleukin, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, immunotherapy (PD-1 inhibitor immunotherapy (pembrolizumab)), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Response rate
Endocrinology, Oncology